Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone
Subjects with schizophrenia or another psychotic disorder according to DSM IV criteria who requires long term antipsychotic therapy
Currently treated with either an atypical antipsychotic, other than risperidone, a conventional depot antipsychotic or oral conventional antipsychotic
Subject has been symptomatically stable on a stable dose of an antipsychotic the last month
Subject and/or patient's relative, guardian or legal representative has signed the informed consent form
You may not be if
First antipsychotic treatment ever
On clozapine during the last 3 month
Serious unstable medical condition
History or current symptoms of tardive dyskinesia
History of neuroleptic malignant syndrome
Pregnant or breast-feeding female
Female patient of childbearing potential without adequate contraception.
Participation in an investigational drug trial in the 30 days prior to selection
Known intolerance/non-responder to risperidone
Clareo Health | Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone
